Cargando…
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases
BACKGROUND AND OBJECTIVE: Demographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) an...
Autores principales: | Brown, Kevin K., Inoue, Yoshikazu, Flaherty, Kevin R., Martinez, Fernando J., Cottin, Vincent, Bonella, Francesco, Cerri, Stefania, Danoff, Sonye K., Jouneau, Stephane, Goeldner, Rainer‐Georg, Schmidt, Martin, Stowasser, Susanne, Schlenker‐Herceg, Rozsa, Wells, Athol U. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306931/ https://www.ncbi.nlm.nih.gov/pubmed/35224814 http://dx.doi.org/10.1111/resp.14231 |
Ejemplares similares
-
Reply to comment on “The natural history of progressive fibrosing interstitial lung diseases”
por: Brown, Kevin K., et al.
Publicado: (2020) -
The natural history of progressive fibrosing interstitial lung diseases
por: Brown, Kevin K., et al.
Publicado: (2020) -
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial
por: Flaherty, Kevin R., et al.
Publicado: (2022) -
Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease
por: Flaherty, Kevin R, et al.
Publicado: (2017) -
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases
por: Cottin, Vincent, et al.
Publicado: (2021)